Literature DB >> 16048980

In vitro interaction of posaconazole and caspofungin against clinical isolates of Candida glabrata.

E R Oliveira1, A W Fothergill, W R Kirkpatrick, B J Coco, T F Patterson, S W Redding.   

Abstract

Combinations of caspofungin and posaconazole were evaluated by fractional inhibitory concentration index against 119 Candida glabrata isolates. Synergy was seen in 18% of all isolates and in 4% of fluconazole-resistant isolates at 48 h without evidence of antagonism. This antifungal combination may have utility against this organism.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16048980      PMCID： PMC1196222          DOI： 10.1128/AAC.49.8.3544-3545.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  11 in total

1.  Guidelines for treatment of candidiasis.

Authors:  Peter G Pappas; John H Rex; Jack D Sobel; Scott G Filler; William E Dismukes; Thomas J Walsh; John E Edwards
Journal:  Clin Infect Dis       Date:  2003-12-19       Impact factor: 9.079

Review 2.  Combination antifungal therapy against Candida species: the new frontier--are we there yet?

Authors:  J A Vazquez
Journal:  Med Mycol       Date:  2003-10       Impact factor: 4.076

3.  Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000.

Authors:  M A Pfaller; D J Diekema; R N Jones; S A Messer; R J Hollis
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

4.  Application of CHROMagar Candida for rapid screening of clinical specimens for Candida albicans, Candida tropicalis, Candida krusei, and Candida (Torulopsis) glabrata.

Authors:  M A Pfaller; A Houston; S Coffmann
Journal:  J Clin Microbiol       Date:  1996-01       Impact factor: 5.948

5.  Natural defenses against Candida colonization breakdown in the oral cavities of the elderly.

Authors:  S R Lockhart; S Joly; K Vargas; J Swails-Wenger; L Enger; D R Soll
Journal:  J Dent Res       Date:  1999-04       Impact factor: 6.116

6.  Development of fluconazole resistance in Candida albicans causing disseminated infection in a patient undergoing marrow transplantation.

Authors:  K A Marr; T C White; J A van Burik; R A Bowden
Journal:  Clin Infect Dis       Date:  1997-10       Impact factor: 9.079

7.  Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole.

Authors:  K A Marr; K Seidel; T C White; R A Bowden
Journal:  J Infect Dis       Date:  2000-01       Impact factor: 5.226

8.  In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates.

Authors:  M A Pfaller; D J Diekema; S A Messer; R J Hollis; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

Review 9.  Current and emerging azole antifungal agents.

Authors:  D J Sheehan; C A Hitchcock; C M Sibley
Journal:  Clin Microbiol Rev       Date:  1999-01       Impact factor: 26.132

10.  Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis.

Authors:  Steve Hernandez; José L López-Ribot; Laura K Najvar; Dora I McCarthy; Rosie Bocanegra; John R Graybill
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191
View more
  7 in total

1.  Synergistic effect of posaconazole and caspofungin against clinical zygomycetes.

Authors:  María Guembe; Jesús Guinea; Teresa Peláez; Marta Torres-Narbona; Emilio Bouza
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

2.  Synergistic activities of three triazoles with caspofungin against Candida glabrata isolates determined by time-kill, Etest, and disk diffusion methods.

Authors:  Nuri Kiraz; Ilknur Dag; Mustafa Yamac; Abdurrahman Kiremitci; Nilgun Kasifoglu; Yasemin Oz
Journal:  Antimicrob Agents Chemother       Date:  2010-03-01       Impact factor: 5.191

3.  The strength of synergistic interaction between posaconazole and caspofungin depends on the underlying azole resistance mechanism of Aspergillus fumigatus.

Authors:  Eleftheria Mavridou; Joseph Meletiadis; Antony Rijs; Johan W Mouton; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2015-01-12       Impact factor: 5.191

4.  Activity of Combined Antifungal Agents Against Multidrug-Resistant Candida glabrata Strains.

Authors:  Laura Bedin Denardi; Jéssica Tairine Keller; Vanessa Oliveira; Débora Alves Nunes Mario; Janio Morais Santurio; Sydney Hartz Alves
Journal:  Mycopathologia       Date:  2017-05-10       Impact factor: 2.574

5.  Posaconazole: A new agent for the prevention and management of severe, refractory or invasive fungal infections.

Authors:  Andrea V Page; W Conrad Liles
Journal:  Can J Infect Dis Med Microbiol       Date:  2008-07       Impact factor: 2.471

Review 6.  Posaconazole: An Update of Its Clinical Use.

Authors:  Simon Leung; Mara N Poulakos; Jade Machin
Journal:  Pharmacy (Basel)       Date:  2015-10-21

7.  Posaconazole exhibits in vitro and in vivo synergistic antifungal activity with caspofungin or FK506 against Candida albicans.

Authors:  Ying-Lien Chen; Virginia N Lehman; Anna F Averette; John R Perfect; Joseph Heitman
Journal:  PLoS One       Date:  2013-03-05       Impact factor: 3.240
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.